BlackRock Inc. Purchases New Shares in Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• BlackRock acquired a major stake in Enanta Pharmaceuticals, purchasing 3.24 million shares worth approximately $47.3 million and gaining an 11.16% ownership position. Institutional investors collectively own 94.99% of the company.
• Analyst sentiment is mixed: six analysts rate ENTA a Buy while one rates it a Sell, resulting in a “Moderate Buy” consensus and a $19.50 average price target.
• Enanta reported weaker-than-expected quarterly results, with an adjusted loss of $0.67 per share versus the $0.51 consensus estimate and revenue of $14.36 million versus expectations of $16.76 million.

BlackRock Inc. bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,244,448 shares of the biotechnology company's stock, valued at approximately $47,304,000. BlackRock Inc. owned approximately 11.16% of Enanta Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth $32,000. Seven Fleet Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $36,000. Strs Ohio acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $50,000. Clearstead Trust LLC acquired a new stake in Enanta Pharmaceuticals during the second quarter worth about $74,000. Finally, Quarry LP purchased a new position in Enanta Pharmaceuticals during the third quarter worth about $81,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ENTA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $19.50.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $13.33 on Tuesday. Enanta Pharmaceuticals, Inc. has a 12 month low of $7.05 and a 12 month high of $17.15. The firm has a market capitalization of $388.24 million, a PE ratio of -5.53 and a beta of 0.98. The business's fifty day moving average price is $13.59 and its 200 day moving average price is $13.47.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million during the quarter, compared to analysts' expectations of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. As a group, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.